Back

CaCO3 Nanoparticles Delivering MicroRNA-200c Suppress Oral Squamous Cell Carcinoma

Ding, Q.; Remy, M. T.; Upara, C.; Hu, J.; Mata, A. M.; Haes, A. J.; Lanzel, E.; Sun, H.; Buchakjian, M.; Hong, L.

2023-10-05 bioengineering
10.1101/2023.10.05.561110 bioRxiv
Show abstract

MicroRNA (miR)-200c suppresses the initiation and progression of oral squamous cell carcinoma (OSCC), the most prevalent head and neck cancer with high recurrence, metastasis, and mortality rates. However, miR-200c-based gene therapy to inhibit OSCC growth and metastasis has yet to be reported. To develop an miR-based gene therapy to improve the outcomes of OSCC treatment, this study investigates the feasibility of plasmid DNA encoding miR-200c delivered via non-viral CaCO3-based nanoparticles to inhibit OSCC tumor growth. CaCO3-based nanoparticles with various ratios of CaCO3 and protamine sulfate (PS) were utilized to transfect pDNA encoding miR-200c into OSCC cells and the efficiency of these nanoparticles was evaluated. The proliferation, migration, and associated oncogene production, as well as in vivo tumor growth for OSCC cells overexpressing miR-200c were also quantified. It was observed that, while CaCO3-based nanoparticles improve transfection efficiencies of pDNA miR-200c, the ratio of CaCO3 to PS significantly influences the transfection efficiency. Overexpression of miR-200c significantly reduced proliferation, migration, and oncogene expression of OSCC cells, as well as the tumor size of cell line-derived xenografts (CDX) in mice. In addition, a local administration of pDNA miR-200c using CaCO3 delivery significantly enhanced miR-200c transfection and suppressed tumor growth of CDX in mice. These results strongly indicate that the nanocomplexes of CaCO3/pDNA miR-200c may potentially be used to reduce oral cancer recurrence and metastasis and improve clinical outcomes in OSCC treatment. (227 words)

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Bioactive Materials
20 papers in training set
Top 0.1%
13.1%
2
ACS Applied Bio Materials
24 papers in training set
Top 0.1%
6.9%
3
Journal of Controlled Release
44 papers in training set
Top 0.2%
5.6%
4
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.2%
4.5%
5
Journal of Nanobiotechnology
14 papers in training set
Top 0.1%
3.3%
6
Pharmaceutics
24 papers in training set
Top 0.2%
3.3%
7
Biomaterials Advances
22 papers in training set
Top 0.2%
3.3%
8
Advanced Functional Materials
46 papers in training set
Top 0.4%
3.2%
9
Scientific Reports
3612 papers in training set
Top 37%
2.8%
10
ACS Biomaterials Science & Engineering
37 papers in training set
Top 0.3%
2.8%
11
Materials Today Bio
20 papers in training set
Top 0.2%
2.8%
50% of probability mass above
12
Advanced Therapeutics
17 papers in training set
Top 0.1%
2.5%
13
Biomaterials Science
24 papers in training set
Top 0.3%
2.5%
14
PLOS ONE
5266 papers in training set
Top 44%
2.2%
15
Biomaterials
84 papers in training set
Top 0.7%
2.2%
16
Journal of Biomedical Materials Research Part A
20 papers in training set
Top 0.2%
2.2%
17
Advanced Healthcare Materials
85 papers in training set
Top 0.9%
1.8%
18
Molecular Therapy
81 papers in training set
Top 1%
1.1%
19
Cells
249 papers in training set
Top 4%
1.1%
20
Acta Biomaterialia
92 papers in training set
Top 0.8%
1.1%
21
ACS Applied Materials & Interfaces
39 papers in training set
Top 0.7%
1.1%
22
Colloids and Surfaces B: Biointerfaces
10 papers in training set
Top 0.2%
1.1%
23
Cellular and Molecular Bioengineering
22 papers in training set
Top 0.4%
1.0%
24
ACS Nano
113 papers in training set
Top 2%
0.9%
25
PeerJ
308 papers in training set
Top 10%
0.9%
26
Science Advances
1243 papers in training set
Top 29%
0.9%
27
Advanced Science
286 papers in training set
Top 9%
0.9%
28
Bioconjugate Chemistry
20 papers in training set
Top 0.3%
0.9%
29
Stem Cell Research & Therapy
30 papers in training set
Top 0.7%
0.9%
30
Frontiers in Cardiovascular Medicine
53 papers in training set
Top 2%
0.9%